Boston Scientific invests in Corautus again
This article was originally published in Clinica
Executive Summary
Boston Scientific will increase its equity investment in Corautus Genetics, the Atlanta, Georgia-based company with which it is collaborating on gene therapy technology development to treat severe coronary artery disease.